Aligos Q1 net loss $35.6M (-$0.84/sh); HBV STOPS/ASO programs terminated; cash $183.2M

Aligos Therapeutics, Inc.

2023-Q1 EPS reported -$0.84

Net loss of $35.6M ($0.84 per share) vs $27.7M ($0.74) in Q1 2021; R&D expense rose to $31.7M.
Cash, equivalents and marketable securities $183.2M at March 31, 2022; runway into first half 2024.
Terminated STOPS and ASO HBV programs in Q1 due to insufficient antiviral activity and poor tolerability.
ALG-000184 (HBV CAM) 28-day top-line data expected Q2 2022; 12-week cohort initiating Q3.
COVID PI candidate ALG-097558 7-20x more potent than nirmatrelvir vs variants; Phase 1 CTA planned H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.